
Patients with a variety of zzso were treated in phase I clinical trials of zzso zzso A zzso zzso schedules consisting of either zzso doses for 28 days zzso zzso or three times weekly for 28 days zzso zzso zzso monitoring of several immune functions was done on these patients, with rigorously standardized zzso and determination of inherent zzso of function for each zzso The zzso performed were natural killer zzso cell zzso zzso zzso activity, zzso responses to zzso A zzso zzso and mixed zzso culture, and an analysis of changes in zzso populations as determined using a panel of zzso zzso and flow zzso No appreciable increase in zzso activity was observed on any of the treatment regimens, and an unexpected observation was the depression of activity in a substantial proportion zzso of zzso In contrast, zzso function, as measured in an zzso of growth zzso of tumor target cells, was found to be elevated in zzso of the zzso zzso responses were depressed in most patients in response to both zzso A and the mixed zzso zzso Cell surface marker studies revealed an increase in the percentage of zzso positive cells in the majority of patients studied and a transient increase in cells reacting with the zzso zzso The data have been analyzed in terms of their relationship to dose and schedule of administration, and the depression of zzso activity was shown to be greatest at the highest doses and more frequent schedule of zzso 

